Clinical trials: Neoplasms, Pharyngeal
Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- 2018/00947 (NCT03813394)
- Testing
- pembrolizumab, bevacizumab
- Where
- Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma (NPC), Screening
"Xijiang Project" Screening Cohort for NPC
The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and…
- Trial name
- NCT06787456
- Testing
- EBV antibodies test, EBV DNA test, epidemiological information survey
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Ming-Yuan Chen
Vaginal Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer
- Trial name
- NCT02280811
- Testing
- Fludarabine, Cyclophosphamide, E6 TCR
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial
This clinical trial evaluates how decreasing the dose of radiation to the elective neck (areas of lymph nodes not directly involved in the cancer) impacts treatment outcomes in patients with human papillomavirus (HPV)-related…
- Trial name
- NCT07178301
- Testing
- Computed Tomography, Nasopharyngeal Laryngoscopy, Positron Emission Tomography
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University
Locally Advanced HPV Positive Oropharynx Cancer
Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer
The purpose of this study is to establish the efficacy and toxicity of low dose chemoradiotherapy after induction chemotherapy in patients with locally advanced HPV+ oropharynx cancer and establish prognostic factors that would…
- Trial name
- NCT02945631
- Testing
- PTV56, PTV50.4
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Head and Neck Cancer
Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers
Objectives: Primary Aim: Examine the feasibility of a dyadic yoga program in 40 Head and Neck Cancer (HNC) patients undergoing radiotherapy (RT) and their family caregivers. Secondary Aims: 1.
- Trial name
- NCT03114501
- Testing
- Yoga, Yoga Questionnaire, Symptom Questionnaires
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- M.D. Anderson Cancer Center
Hypopharyngeal Neoplasms, Laryngeal Neoplasms
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract
To assess the use of the da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) in transoral surgeries in patients with benign and malignant lesions of the oral cavity and laryngopharynx.
- Conditions
- Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Cancers
- Trial name
- NCT00721539
- Testing
- da Vinci Surgical Robot Platform, Transoral Robotic Surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to swallowing exercises to prevent future disease.
- Conditions
- Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT03010150
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 471 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
This is a randomized Phase II trial to study the effectiveness and toxicity of neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy…
- Trial name
- NCT03925090
- Testing
- Cisplatin+Toripalimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia
Hypothesis: In the management of advanced oesophageal cancer, to determine if a shorter regime of external beam radiotherapy (using higher daily doses, and combined with intraluminal high dose rate brachytherapy) is not inferior…
- Trial name
- NCT00665197
- Testing
- Protracted Course Radiotherapy, Short Course Radiotherapy
- Where
- 7 sites in Canada, China and 5 more
- Volunteers
- 200 people
- Sponsor
- International Atomic Energy Agency
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Adebrelimab and Chemoradiotherapy in High-risk LANPC
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
- Trial name
- NCT06349889
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
Current radiotherapy guidelines and consensus statements uniformly recommend elective region irradiation (ERI) as the standard strategy for nasopharyngeal carcinoma (NPC).
- Trial name
- NCT05145660
- Testing
- intensity-modulated radiotherapy (IMRT) with reduced-volume, Chemotherapy
- Where
- China
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Yi Junlin
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Oropharyngeal Cancer
Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
Cancer of the oropharynx (middle, side and back walls of the throat; back of the tongue; soft palate, and tonsils), or oropharyngeal squamous cell carcinoma (OPSCC), has been on the rise in the United States.
- Trial name
- NCT02147418
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Nasopharyngeal Cancer
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
The purpose of this trial is to study the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in high risk NPC patients with residual EBV DNA following primary radiotherapy with or without concurrent cisplatin.
- Trial name
- NCT00370890
- Testing
- Adjuvant chemotherapy (gemcitabine and cisplatin)
- Where
- 6 sites in Hong Kong
- Volunteers
- 104 people
- Sponsor
- Chinese University of Hong Kong
Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms
Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma
Warburg effect is an important feature of tumors,and genetic variation is one of the main factors of individual differences to radiotherapy treatment response for nasopharyngeal carcinoma(NPC).
- Conditions
- Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms, Radiosensitivity
- Trial name
- NCT02481089
- Testing
- validation group
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Esophageal Neoplasms, Dysphagia
Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.
Esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. The main symptom of esophageal cancer is dysphagia, associated or not with weight loss.
- Trial name
- NCT06070376
- Testing
- Fully Covered Esophageal Prosthesis (FC-SEMS), Partially Covered Esophageal Prosthesis (PC-SEMS)
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Nasopharyngeal Carcinoma
OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy
This is a lead-in dose escalation study to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), and recommended Phase II dose of OPB-51602 administered on a weekly basis in subjects with advanced…
- Trial name
- NCT02058017
- Testing
- OPB-51602
- Where
- Singapore
- Volunteers
- 9 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC
This is a Phase II trial to study the effectiveness and security of cisplatin concurrent chemoradiotherapy plus TIL versus cisplatin concurrent chemoradiotherapy only with IMRT in treating patients with locoregionally advanced…
- Trial name
- TIL (NCT02421640)
- Testing
- Cisplatin+TIL, Cisplatin
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.